· Singmed’s self-developed propellant-free soft mist inhaler platform has been used in a drug-device combination program that completed bioequivalence evaluation in 2021. The platform generates a low-velocity soft mist through a precision nozzle and can be customized for formulation, aerosol performance, dose delivery and device configuration.

· The pocket-sized device is designed to deliver a one-breath inhalable aerosol, aiming to optimize drug delivery efficiency to the lungs, minimize patient coordination and inspiratory force requirements, and enhance patient experience and convenience.

· Utilizing an innovative aerosol technology, this device converts a drug solution into a soft mist consisting of two rotating liquid jets that pass through each other via a precisely-designed two-channel nozzle. This unique soft mist exhibits characteristics such as low velocity, high cohesion, long residence time, and small particle size, which facilitate effective distribution of drugs in the lungs.

· SMI offers several advantages over other inhalers in terms of pulmonary deposition rate, oropharyngeal deposition rate, regional distribution, dose consistency, respiratory parameters, and patient satisfaction. By improving drug deposition in specific areas of the lungs like small airways, this device enhances treatment effectiveness while reducing potential side effects.

Quote：R. Dalby, M. Spallek, and T. Voshaar, “A review of the development of Respimat Soft Mist Inhaler,” International Journal of Pharmaceutics, vol. 283, no. 1-2, pp. 1–9, 2004.